Article

Avedro, Inc., company update: Epi-on crosslinking (CXL) and PiXL technology

Author(s):

Julianne Mobilian
Conferences|ASCRS

ICYMI: Here's what's in the 2019 pipeline

Rajesh Rajpal, MD, Chief Medical Officer of Avedro, Inc., provides a company update on Epi-on crosslinking (CXL) and PiXL technology during the 2019 ASCRS conference in San Diego.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
EyeCool Therapeutics appoints Vance Thompson, MD, to board of directors
September 3rd 2025

EyeCool Therapeutics appoints Vance Thompson, MD, to board of directors

3 Things You Should Know About the GA Pipeline
September 3rd 2025

NK Insights: An Interactive Corneal Sensitivity Testing Workshop

(Image credit: AdobeStock/NicoElNino) Dialing in precision: Astigmatism management with arcuate incisions
September 3rd 2025

Dialing in precision: Astigmatism management with arcuate incisions

3 Things You Should Know About the GA Pipeline
September 3rd 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point
September 3rd 2025

Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point

OKYO Pharma receives $1.9 million in non-dilutive funding
September 3rd 2025

OKYO Pharma receives $1.9 million in non-dilutive funding

© 2025 MJH Life Sciences

All rights reserved.